Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-880 in type 1 diabetes with impaired hypoglycemic awareness
2024-513929-23-00Phase 3Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2024
- Modality
- Beta Cells → Tissue Cells → Other Cell Types → Cell Therapies, Stem Cell Therapies → Cell Therapies
- Countries
- 9
01
Overview
Phase 3, open-label trial of zimislecel in diabetes mellitus type 1 (T1D) (3 cohorts), sponsored by Vertex Pharmaceuticals. Primary endpoints: Part A - Safety and tolerability and Insulin independence at Day 365 (Part B and C). Planned start Oct 2024; status: authorised.
02
Drugs
zimislecel
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-513929-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513929-23-00.